Exact Therapeutics has announced that the phase I ACTIVATE study evaluating ACT in patients with metastatic colorectal cancer has enrolled the first patient following temporary suspension due to the COVID-19 pandemic.
To date six patients have now been enrolled in the study being led by Professor Udai Banerji at the Royal Marsden Hospital (RMH) in London.
“We are delighted to restart enrolment in the ACTIVATE study and look forward to continuing the clinical evaluation of the ACT platform in patients with metastatic colorectal cancer,” says Udai Banerji, NIHR Professor of Molecular Cancer Pharmacology and Honorary Consultant in Medical Oncology, Royal Marsden Hospital.
The ACTIVATE study details
● The first in man ACTIVATE study is a phase I evaluation of the innovative platform technology, Acoustic Cluster Therapy (ACT) in the treatment of patients with metastatic colorectal and pancreatic cancer.
● This study is assessing the safety, tolerability and preliminary efficacy of ACT co-administered with standard of care chemotherapy in these patients.
● To date the study has enrolled 6 patients at RMH with Professor Udai Banerji as principal investigator.
● Additional centres in the UK and Norway are planned as the study progresses.
“We are very grateful to Professor Banerji and the entire team at the Royal Marsden Hospital for their commitment and dedication to the ACTIVATE study with the enrolment of the first patient following the suspension due to Covid-19. This important study will provide important insights regarding the safety, tolerability, pharmacokinetics and preliminary efficacy of ACT in the cancer setting,” says EXACT Therapeutics CEO, Dr Rafiq Hasan.
Photo of Rafiq Hasan: Exact Therapeutics